After the departure of Shan Guohong, Pfizer's development in the Chinese market will become more and more difficult. On May 10, Pfizer China announced that Pfizer Global Innovation Pharmaceuticals General Manager Shan Guohong had left. At a time when some domestic pharmaceutical companies attach importance to the development of innovative drugs and the level of generic drugs, and the advantages of foreign-funded pharmaceutical companies are becoming less obvious, Pfizer faces problems such as slowing performance growth, product aging, and drug patent expiration. Shan Guohong was the core figure who helped Pfizer to explore the Chinese market. His departure will make Pfizer more difficult in China.

The main will leave

Shan Guohong, the key figure driving Pfizer to open the Chinese market, announced his departure, which is only one year after he took over as the general manager of Pfizer Global Innovation Pharmaceuticals China. Around 2016, Pfizer divided its global business into two major groups: core medical and innovative medical. In June of the same year, Shan Guohong officially took the position of general manager of Pfizer Global Innovation Pharmaceuticals China. The innovative medical care that Shan Guohong is responsible for covers cancer, vaccine, immune inflammation, internal medicine and rare diseases.

Shan Guohong served as the general manager of Innovative Healthcare and served as the president of Pfizer Cancer Greater China and the vice president of Pfizer China. He was responsible for leading the oncology business in China, Hong Kong and Macau and achieved good results. Pfizer said in an internal email at the time, "In the past five years, Shan Guohong successfully led the launch of Secret in China and quickly made China the second largest market in the world." It took him another 86 days to pass the complicated approval process of the Chinese government and go public, which is another important achievement for him."

A satisfactory resume and more than 20 years of experience in the pharmaceutical industry, so that Shan Guohong has the capital to be the general manager of innovative medicine. After taking office, the single-country Hong will bring the Pfizer's 13-valent vaccine back to the Chinese market. This vaccine is the only pneumonia vaccine for children under two years old in the Chinese market. Pei's 13-valent vaccine is considered by the outside world to be a "profit cow" by Pfizer.

Shan Guohong is familiar with the Chinese market and will be affected after the announcement of the Pfizer China market. In response to the reasons for the departure of the single country and the impact of the departure of the single country on the Pfizer China market, the Beijing Business Daily reporter contacted the relevant person in charge of Pfizer, but the person in charge said that they would not comment.

Slowdown

Pfizer, the world's largest pharmaceutical manufacturer, is facing a slowdown in performance growth. Since 2012, Pfizer's sales of several best-selling products have declined due to the expiration of some patents and fierce market competition.

According to the data, in 2016, 11 of the 18 major products Pfizer sold worldwide had negative growth rates. Pfizer's overall performance has improved as a result of increased sales of new breast cancer drug Ibrance and Xeljanz (tofatinib citrate) for the treatment of adult rheumatoid arthritis. In 2016, Pfizer ranked second in the list of top ten multinational pharmaceutical companies, with total sales revenue of US$52.8 billion and growth rate of 8%.

As far as the domestic market is concerned, Pfizer's performance is not optimistic. The data shows that Pfizer China's performance growth has dropped from 20% in the past few years to the current 10%.

An analyst who did not want to be named said that under the influence of the Chinese government's strict control over drug prices and the elimination of drug additions, there are significant pressures on the development path of foreign pharmaceutical companies such as Pfizer in China. Heavy drugs such as Pfizer and other foreign-funded pharmaceutical companies are facing pressures for patent protection expiration in China. China's medical technology continues to advance, and low-cost generic drugs on the market have a greater impact on foreign pharmaceutical companies. "In the past, the quality of domestic generic drugs was not guaranteed. After the implementation of the consistency evaluation, the quality of generic drugs in some domestic pharmaceutical companies has been greatly improved, and the quality has been guaranteed. It will become increasingly difficult for foreign companies to develop in China."

Glow anti slip tape

Glow Anti Slip Tape

Glow anti slip tape from Jerrytape is based on high durability PET material, coated with long lasting solvent acrylic tape, planted with selected emery grit and combined with bright glow in dark strip. It has the features of good adhesion, super good durability, water proofing and glowing in dark. It`s perfect to be used in dark places, to resist your loved ones from skidding. The material is environmentally friendly, can pass REACH certificate. Our glow anti slip tape is much more durable than many other similar products in the market, service life is 2 years, can withstand 100000+ tramples. We use high quality glow powder to the tape, only need to charge under natural light or sunlight or lamplight for 30minutes, it can glow for 4 hours. Light absorption and luminescence can be repeated.

Glow anti slip tape,Glow in dark anti slip tape,luminous anti slip tape,anti slip glow in dark tape,non slip glow in dark tape

Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.yuhuanptapes.com